Long‐term entecavir or tenofovir disoproxil fumarate therapy in treatment‐naïve chronic hepatitis B patients in the real‐world setting

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2893|22|5|504-510

ISSN： 1352-0504

Source： JOURNAL OF VIRAL HEPATITIS (ELECTRONIC), Vol.22, Iss.5, 2015-05, pp. : 504-510

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B

By  

CANCER, Vol. 121, Iss. 20, 2015-10 ,pp. : 3631-3638

John Wiley & Sons Inc

Access to resources Recommend Favorite

Randomized prospective study showing the non‐inferiority of tenofovir to entecavir in treatment‐naïve chronic hepatitis B patients

By  

HEPATOLOGY RESEARCH, Vol. 48, Iss. 1, 2018-01 ,pp. : 59-68

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy of tenofovir disoproxil fumarate therapy in Chinese chronic hepatitis B patients after multiple antiviral failures

By  

HEPATOLOGY RESEARCH, Vol. 45, Iss. 10, 2015-10 ,pp. : E43-E52

John Wiley & Sons Inc

Access to resources Recommend Favorite

Long-Term Efficacy of Entecavir Plus Adefovir Combination Therapy versus Entecavir Monotherapy in Adefovir Refractory Chronic Hepatitis B Patients with Prior Lamivudine Resistance

By  

Intervirology, Vol. 57, Iss. 1, 2013-08 ,pp. : 8-16

Karger

Access to resources Recommend Favorite

Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 422-428

John Wiley & Sons Inc

Access to resources Recommend Favorite